

ASX ANNOUNCEMENT

15 January 2016

Patent Granted in China

Recce Ltd is pleased to announce that P.R. China Application 200880124515.5 has been granted; patent number ZL200880124515.5 (with payment of maintenance fees) is now official and active until an expiry date of 06 August 2028.

This patent relates to Recce's patent Family 1 in which the Company has previously announced the grant of patents, of similar expiry dates, in USA, Europe, Japan and Australia, respectively.

Combined, these patents give Recce a manufacturing and marketing monopoly for RECCE antibiotics – within approximately 80% of the world pharmaceutical markets.

Dr Graham Melrose, Executive Chairman of Recce Ltd commented, "These substantial developments should significantly increase the current worth of the Company".

As the newly won patent in China already gives the Company all advantages to which it aspires in relation to patents of Family 1 intellectual properties – the divisional application 201410136135.0 in China, will no longer be continued.

Dr Melrose also added, "It must also be remembered that only recently, Recce additionally announced that applications re patents for Family 2 "Copolymer and Method for Treatment of Parenteral Infection" were submitted and are also focused upon worldwide pharmaceutical markets."

For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: +61 8 9253 9800

Media Communication

Karen Oswald – karen.oswald@markocommunications.com.au
Gary Buchholz – gary@markocommunications.com.au
Marko Communications
Tel: +61 423 602 353

About Recce Ltd

Recce, led by Dr Graham Melrose, is a world-leader in synthetic-polymer antibiotics. RECCE antibiotics have been synthesised by an extremely simple and economic method.

RECCE antibiotics have shown in laboratory tests that they have continued activity against bacteria including superbugs, even after repeated use.

Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes and the development of a pilot plant for flow-system manufacture of RECCE antibiotics - that should drive significant value for the Company.

